Study about the Efficacy of Metformin to Immune Function in Cancer Patients

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Metformin is a widely used medication for type 2 diabetes.
• Prior research suggests metformin possesses anti-tumor properties.
• The direct impact of metformin on the human immune system in cancer patients remains under investigation.

Purpose of the Study:

• To assess the efficacy of metformin in modulating the immune system.
• To evaluate metformin's in vivo effects in human cancer patients.
• To determine changes in CD8+ T cell populations as a key indicator of immune response.

Main Methods:

• Clinical study initiated in July 2014.
• Focus on human cancer patients.
• Primary outcome measured by the rate of change in CD8+ T cell populations.

Main Results:

• The study is ongoing, and results are pending.
• Analysis will focus on CD8+ T cell dynamics.
• Cytokine production by CD8+ T cells will be considered.

Conclusions:

• The study aims to provide novel insights into metformin's immunomodulatory role in cancer.
• Findings could inform the use of metformin as an adjunct cancer therapy.
• Further research will elucidate metformin's precise mechanisms of action on anti-tumor immunity.